The Neurodivergent-Hypermobility-Fatigue Cluster: Compounded Metabolic Risk
This is the fourth in a series on the energy biology linking ADHD, autism, and ME/CFS. This article examines why the intersection of neurodivergence and connective tissue hypermobility may represent the highest-risk phenotype for developing ME/CFS after an immune trigger.
1 The cluster is real
These conditions co-occur at rates far above chance:
Autistic individuals are 7.4× more likely to have Ehlers-Danlos syndrome than comparison groups. Clinically assessed joint hypermobility is present in 31% of autistic individuals; HSD/EDS prevalence reaches 39% when clinically assessed (Baeza-Velasco et al. 2025).
In children with hEDS or HSD (n = 201), ADHD was present in 16% overall — rising to 46% by age 17–18. ASD was present in 6% (vs ~2.6% general population) (Kindgren, Quiñones Perez, and Knez 2021).
Joint hypermobility statistically mediates the association between neurodivergence and both dysautonomia and pain. In 109 neurodivergent adults, 51% had generalised joint hypermobility (vs 20% general population). Female neurodivergent prevalence: 69% (Csecs et al. 2022).
2 Why the cluster exists: two independent energy deficits
Each condition in this cluster reduces brain metabolic reserve through a different mechanism. When they co-occur, the effects compound.
2.1 Mechanism 1: Reduced energy PRODUCTION (ASD/ADHD)
A meta-analysis of 204 studies found systemic mitochondrial dysfunction in autism spectrum disorder (Frye et al. 2024):
- Elevated lactate (17% of ASD samples)
- Elevated pyruvate (41%)
- Elevated creatine kinase (9%)
- Significant ATP deficit with effect sizes ≥ 0.6 (moderate-to-large)
These are the same electron transport chain impairments documented in ME/CFS. In ASD, they exist as a baseline feature — present before any infectious trigger.
For ADHD, the evidence includes prefrontal glucose hypometabolism (8.1% reduced (Zametkin et al. 1990)), cerebral hypoperfusion (Berthier et al. 2025), and preclinical evidence of mitochondrial impairment (Complex I assembly gene variants: NDUFAF2, UCP2 (Almutairi et al. 2024)).
2.2 Mechanism 2: Reduced energy DELIVERY (hEDS/POTS)
Connective tissue laxity leads to: 1. Venous pooling (blood pools in the legs when upright) 2. Reduced venous return → reduced cardiac output 3. Reduced cardiac output → reduced cerebral perfusion 4. Chronic sympathetic activation to compensate → additional ATP drain
This is not just a standing problem. It is a chronic energy delivery deficit that operates even during cognitive work. The brain receives less fuel per unit time.
3 The compound effect
A person with ASD + hEDS has two independent mechanisms reducing brain energy simultaneously:
- Mitochondrial dysfunction → reduced ATP production (the factory is impaired)
- Cerebral hypoperfusion → reduced ATP delivery (the supply chain is impaired)
Under this model, the effects are multiplicative rather than additive. If ASD reduces production capacity by 12% and hEDS reduces delivery by 8%:
Compound effect: 0.88 × 0.92 = 0.81 → 19% total reduction
Add iron deficiency (common in both ADHD and ASD):
0.88 × 0.92 × 0.90 = 0.73 → 27% total reduction
(These percentages are illustrative estimates demonstrating compounding logic, not empirically measured values. The multiplicative model assumes the deficits are independent — in reality they could be subadditive, additive, or partially overlapping. The actual magnitudes and interaction type remain to be quantified.)
A person with ASD + hEDS + iron deficiency may be operating at 73% of normal metabolic capacity. Before any virus arrives.
4 BH4 as the molecular bridge
The BH4 (tetrahydrobiopterin) pathway connects these conditions at the molecular level:
- ASD: Consistently lower BH4 in biological samples vs controls. BH4 supplementation shows potential in some ASD trials.
- ADHD: High dopaminergic demand increases BH4 consumption.
- hEDS/POTS: Oxidative stress from ischemia-reperfusion oxidises BH4 to its inactive form (BH2).
BH4 is required for both neurotransmitter synthesis (dopamine, serotonin) AND nitric oxide production (vascular tone). Low BH4 impairs the brain’s ability to make signal molecules AND to regulate its own blood flow (Colpani Filho et al. 2025).
5 The infection trigger: compounded vulnerability
When COVID, EBV, or influenza hits a person with this cluster, the immune response imposes metabolic demands on a system already operating near its limits. Cytokine production, lymphocyte proliferation, neuroinflammation — all draw from the same limited energy pool.
In someone at 73% capacity, the additional immune demand may push them below the critical threshold for self-sustaining mitochondrial damage. The feed-forward cycle initiates. Post-infectious fatigue doesn’t resolve.
The prediction is testable: people with more metabolic reserve reducers should have higher ME/CFS incidence after matched infections. ASD + hEDS + iron deficiency → higher risk than ASD alone → higher risk than neurotypical controls.
This has never been tested directly. The data exists in hEDS registries and post-COVID cohorts. The analysis hasn’t been done.
6 Neurodivergence as post-COVID risk factor: preliminary evidence
A 2025 cross-sectional study of 267 healthcare workers found that higher autistic trait scores — specifically the sensory reactivity subscale — predicted COVID-19 symptoms lasting longer than 12 weeks (Raw et al. 2025). This was independent of formal autism diagnosis.
The finding is dimensional: it operates on a spectrum of autistic traits, not just at the diagnostic threshold. Under the metabolic reserve model, any degree of neurodivergent biology that increases baseline neural energy consumption narrows the margin for absorbing an immune insult.
Limitations: This is a small cross-sectional study that cannot establish causation. The design cannot rule out alternative explanations — autistic traits may correlate with different symptom reporting patterns, healthcare-seeking behaviour, or occupational exposures rather than biological vulnerability.
7 What is modifiable in this cluster
Not all of this is fate. Several components of the compound deficit are correctable:
| Component | Intervention | Cost |
|---|---|---|
| Iron status | Ferritin target >50–100 ng/mL; IV iron if oral intolerant | Low |
| Cerebral perfusion | Compression garments, fluid/salt loading, reclined cognitive work | Low |
| BH4 recycling support | Folinic acid, vitamin C, iron (supports DHPR enzyme) | Low |
| POTS management | Standard protocol (midodrine, fludrocortisone, or non-pharmacological) | Moderate |
| Direct BH4 | Sapropterin for confirmed GCH1 carriers | High |
Note: This table presents a research-stage mechanistic framework. Midodrine, fludrocortisone, and sapropterin are prescription medications with specific indications and contraindications. Discuss any intervention with a qualified clinician.
The framing matters. Treating POTS as a standalone diagnosis misses the point. In this cluster, POTS management is metabolic reserve building. Every point of cerebral blood flow recovered is energy the brain can use for thinking, working, living.
Part 4 of a series on the energy biology linking ADHD, autism, and ME/CFS.